AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 AUG 9 - (NewsRx Network) -- New data show that [Zomig.sup.R] (zolmitriptan), produced by AstraZeneca (AZN), is effective in treating migraine regardless of its relationship to menses.
The data were released at the American Headache Society Meeting in New York City, New York, on June 30, 2001. Sixty percent of women who are migraine sufferers experience migraine during, or right after, their menstrual cycles.
"There is a perception that migraine attacks related to menses are more severe and resistant to acute treatment than those unrelated to menses, but there is little existing clinical data to support this," said Susan Abu-Shakra, MD, AstraZeneca. "However, these headaches may feel worse due to bloating, cramping, and other symptoms that accompany menses. Zomig demonstrates equal efficacy in the treatment of migraine associated with a woman's menstrual cycle and in migraine unrelated to menstruation."
Overall, up to 14% of women who suffer from migraine are afflicted with headaches only during their menstrual cycle, suggesting there is a correlation between hormonal fluctuations and migraine headache. Approximately, 33% of women with migraine start getting headaches at or soon after menarche (the onset of menstruation at puberty).
The analysis of a female subpopulation showed that Zomig is a consistently effective treatment for migraine regardless of its relationship to menses. Zomig was significantly more effective than placebo in the treatment of moderate or severe ...
Source: HighBeam Research, Drug Efficacy Is Unaffected By Menstrual Cycle In Women.(Zomig...